Dupilumab 200 mg was efficacious in children (6–11 years) with moderate‐to‐severe asthma for up to 2 years: EXCURSION open‐label extension study.

Autor: Phipatanakul, Wanda, Vogelberg, Christian, Bacharier, Leonard B., Dell, Sharon, Altincatal, Arman, Gall, Rebecca, Ledanois, Oliver, Sacks, Harry, Jacob‐Nara, Juby A., Deniz, Yamo, Rowe, Paul J.
Zdroj: Pediatric Pulmonology; Nov2024, Vol. 59 Issue 11, p2976-2983, 8p
Databáze: Complementary Index
Externí odkaz: